Last checked at 25 Sep 2014 11:03
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Synairgen Share News (SNG)
SNG Share
Price
SNG Share
News
SNG Share
Chat
SNG Share
Trades18
SNG
Live RNS
SNG Share
Charts
SNG Level 2
Console
SNG Live
Share Price
SNG Broker
Ratings
SNG Directors
Deals
SNG Financial
Diary
SNG
Fundamentals
SNG Short
Positions
SNG
Media
Synairgen Information
Share Price Information for Synairgen (SNG)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
6.20
Bid:
5.52
Ask:
7.00
Change:
0.08 (1.31%)
Spread:
1.48 (26.812%)
Open:
6.20
High:
6.20
Low:
6.20
Prev. Close:
6.12
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Tuesday broker round-up UPDATE
Tue, 21st Oct 2014 08:50
African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating.Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy recommendation.Antofagasta: JP Morgan reduces target price from 830p to 760p maintaining a neutral rating.BHP Billiton: JP Morgan reduces target price from 2250p to 2180p keeping a neutral rating.Brooks Macdonald: Numis reduces target price from 1550p to 1470p retaining its hold recommendation.Brown (N) Group: Credit Suisse reduces target price from 518p to 330p downgrading to neutral.BT Group: Goldman Sachs cuts target price from 620p to 600p retaining a strong buy recommendation.Cable & Wireless Communications: JP Morgan lowers target price from 53p to 50p and maintains a neutral rating.Dairy Crest: UBS cuts target price from 460p to 410p retaining a neutral rating.Devro: N+1 Singer upgrades from hold to buy with a target price of 257p.Dialight: Investec upgrades from sell to hold with a target price of 850p.GKN: JP Morgan reduces target price from 460p to 370p reiterating its overweight rating.Go Ahead Group: Investec increases target price from 2670p to 2750p and leaves its buy recommendation unchanged.Hellermann Tyton: UBS initiates with a target price of 300p and a neutral rating.Hochschild Mining: JP Morgan cuts target price from 185p to 150p keeping its neutral rating.Informa: Westhouse Securities upgrades from neutral to buy with a target price of 554p.Inmarsat: JP Morgan ups target price from 810p to 840p and reiterates an overweight rating.Kazakhmys: JP Morgan cuts target price from 400p to 375p and stays with its overweight rating.Lloyds Banking Group: Credit Suisse shifts target price from 68p to 72p and stays with its neutral rating.NMC Health: Investec initiates with a target price of 610p and a buy recommendation.Petropavlovsk: JP Morgan lowers target price from 20p to 10p and reiterates an underweight rating.President Energy: Canaccord Genuity moves target price from 50p to 60p and retains its speculative buy recommendation.Redefine: Deutsche Bank lowers target price from 56p to 53p keeping its hold recommendation.Rightmove: Credit Suisse reduces target price from 3100p to 2655p and reiterates an outperform rating.Standard Chartered: Credit Suisse reduces target price from 1150p to 1020p and maintains an underperform rating.Synairgen: N+1 Singer initiates with a target price of 49p and a buy recommendation.Talk Talk Telecom: Goldman Sachs cuts target price from 450p to 435p and maintains a buy recommendation.Telecity Group: JP Morgan ups target price from 900p to 925p and keeps an overweight rating.Travis Perkins: UBS reduces target price from 2100p to 2000p reiterating a buy recommendation. Deutsche Bank lowers target price from 1901p to 1898p and keeps its hold recommendation.Vedanta Resources: JP Morgan reduces target price from 1130p to 1030p and retains a neutral rating.William Hill: Canaccord Genuity moves target price from 350p to 365p and keeps a hold recommendation.Zoopla Property: Credit Suisse cuts target price from 290p to 270p leaving its outperform rating unaltered.
More News
4 Jul 2014 12:11
Synairgen raises funds to develop AstraZeneca drug
Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is
Read more4 Jul 2014 07:21
15 Jun 2014 12:28
Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property
Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff
Read more12 Jun 2014 16:37
MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions
LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.
Read more
12 Jun 2014 10:23
TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014
LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more
12 Jun 2014 08:25
London open: Mining stocks pull FTSE 100 lower ahead of data
- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound
Read more12 Jun 2014 07:42
AstraZeneca signs licence deal with Synairgen
British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de
Read more12 Jun 2014 07:36
UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen
LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.
AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology
12 Jun 2014 06:52
AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen
LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections
Read more20 Mar 2014 12:47
Synairgen Pretax Loss Narrows On Expenses
LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye
Read more5 Mar 2014 11:31
Synairgen Jumps As It Raises Cash While Progressing Licensing Talks
LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery
Read more5 Mar 2014 08:31
UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool
LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.
Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi
5 Dec 2012 11:10
Synairgen reports 'significant progress'
Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote
Read more